Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.000171 | uM | 12000.164 | 1.0055 | 1.0154 | 0.7152 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.000853 | uM | 12000.164 | 0.9493 | 0.8596 | 0.7152 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.00427 | uM | 12000.164 | 1.0296 | 1.0831 | 0.7152 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.0213 | uM | 12000.164 | 0.9371 | 0.8264 | 0.7152 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.107 | uM | 12000.164 | 0.9008 | 0.7282 | 0.7152 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.533 | uM | 12000.164 | 0.9146 | 0.7654 | 0.7152 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 2.67 | uM | 12000.164 | 0.8548 | 0.6061 | 0.7152 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 13.3 | uM | 12000.164 | 0.8334 | 0.5501 | 0.7152 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 66.7 | uM | 12000.164 | 0.5251 | -0.1874 | 0.7152 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.000171 | uM | 12084.164 | 0.9885 | 0.9812 | 1.2250 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.000853 | uM | 12084.164 | 0.9387 | 0.8994 | 1.2250 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.00427 | uM | 12084.164 | 0.9284 | 0.8823 | 1.2250 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.0213 | uM | 12084.164 | 1.0303 | 1.0494 | 1.2250 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.107 | uM | 12084.164 | 0.8125 | 0.6882 | 1.2250 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.533 | uM | 12084.164 | 0.8708 | 0.7863 | 1.2250 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 2.67 | uM | 12084.164 | 0.8732 | 0.7904 | 1.2250 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 13.3 | uM | 12084.164 | 0.6972 | 0.4899 | 1.2250 | |
| HCC1395 | TNBC | Basal B | Everolimus | MTOR | MTOR | 66.7 | uM | 12084.164 | 0.1341 | -0.6121 | 1.2250 | |
| HCC1419 | HER2amp | Luminal | Everolimus | MTOR | MTOR | 0.000171 | uM | 12001.164 | 0.9436 | 0.7670 | 0.4690 | |
| HCC1419 | HER2amp | Luminal | Everolimus | MTOR | MTOR | 0.000853 | uM | 12001.164 | 0.9366 | 0.7395 | 0.4690 | |
| HCC1419 | HER2amp | Luminal | Everolimus | MTOR | MTOR | 0.00427 | uM | 12001.164 | 0.8892 | 0.5570 | 0.4690 | |
| HCC1419 | HER2amp | Luminal | Everolimus | MTOR | MTOR | 0.0213 | uM | 12001.164 | 0.7566 | 0.1035 | 0.4690 | |
| HCC1419 | HER2amp | Luminal | Everolimus | MTOR | MTOR | 0.107 | uM | 12001.164 | 0.6600 | -0.1754 | 0.4690 | |
| HCC1419 | HER2amp | Luminal | Everolimus | MTOR | MTOR | 0.533 | uM | 12001.164 | 0.6744 | -0.1364 | 0.4690 | |
| HCC1419 | HER2amp | Luminal | Everolimus | MTOR | MTOR | 2.67 | uM | 12001.164 | 0.6504 | -0.2008 | 0.4690 |